Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128044 · ClinicalTrials.gov registry record · Phase 1
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Caribou Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06128044 is a Phase 1 study that was terminated before completion, run by Caribou Biosciences. The registered enrollment target is 12 participants.
The verdict
NCT06128044, a Phase 1 study, was terminated before completion, sponsored by Caribou Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of treatment for AML .
Interventions
- DRUG CB-012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128044
The ClinicalTrials.gov registry entry for NCT06128044 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caribou Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CB-012 is the first listed.
NCT06128044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06128044 about?
NCT06128044 is a clinical study titled "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia". CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has ...
What is the current status of trial NCT06128044?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-02-08. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT06128044?
The interventions under investigation include: CB-012 (DRUG).
Who is sponsoring clinical trial NCT06128044?
This trial is sponsored by Caribou Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.